10-Q: Foghorn Therapeutics Narrows Loss, Advances Lilly Pact

Foghorn Therapeutics Inc. reported a reduced net loss and lower operating expenses for the first half of 2025, driven by strategic program adjustments and continued collaboration with Eli Lilly and Company.

Summary

• Net loss for the six months ended June 30, 2025, improved to $36.8 million, down from $48.0 million in the same period of 2024.
• Collaboration revenue increased to $13.5 million for the six months ended June 30, 2025, up from $11.9 million in the prior year period, primarily due to the Lilly Collaboration Agreement.
• Research and development expenses decreased by $5.9 million to $43.4 million for the six months ended June 30, 2025, largely due to the discontinuation of independent FHD-286 development.
• Lilly partnered program expenses increased by $2.6 million, driven by the initiation of the Phase 1 dose escalation study for FHD-909.
• General and administrative expenses decreased by $0.9 million to $14.1 million for the six months ended June 30, 2025.
• Net cash used in operating activities decreased to $45.0 million for the six months ended June 30, 2025, compared to $54.9 million in the prior year period.
• As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $198.7 million.
• The company had an accumulated deficit of $595.0 million as of June 30, 2025.
• A new 10-year lease agreement for 72,846 square feet of laboratory and office space in Watertown, Massachusetts, was entered into in June 2025, with estimated minimum lease payments of $61.0 million.
• The existing Office Lease was amended to reduce fixed payments and shorten the term for a portion of the leased space to December 31, 2026, resulting in an $8.8 million reduction in ROU asset and lease liability.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur significant losses and will require future capital, the financial performance shows improvement with a reduced net loss and lower cash burn. The advancement of the key partnered program (FHD-909) with Eli Lilly and Company is a strong positive, indicating progress in its core strategy. The strategic decision to discontinue FHD-286, while a program setback, reflects prudent resource allocation. The stated cash runway of at least 12 months provides near-term stability.

Positives

• Net loss significantly decreased by $11.2 million for the six months ended June 30, 2025, indicating improved financial performance.
• Collaboration revenue increased, reflecting continued advancement of programs under the Eli Lilly and Company collaboration.
• Research and development expenses decreased due to strategic discontinuation of less promising programs (FHD-286), optimizing resource allocation.
• Net cash used in operating activities decreased, indicating a more efficient cash burn rate.
• The company expects its current cash, cash equivalents, and marketable securities of $198.7 million to fund operations for at least 12 months.
• Advancement of FHD-909 into Phase 1 dose escalation study with Eli Lilly and Company signifies progress in a key partnered program.

Negatives

• The company continues to incur significant operating losses, with an accumulated deficit of $595.0 million as of June 30, 2025.
• Independent development of FHD-286 in AML and uveal melanoma was discontinued, indicating a setback for those specific programs.
• Interest income decreased due to a lower average balance of marketable securities.
• The company will require substantial additional funding through equity offerings, debt financings, or collaborations to support future operations and growth strategy.

Risks

• The company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances, and/or licensing arrangements to continue funding its operations.
• There is no assurance that the company will be able to obtain financing on acceptable terms, or at all, which could force delays, reductions, or elimination of research and development programs or commercialization efforts.
• The terms of any future financing may adversely affect the holdings or rights of the company's stockholders.
• Arrangements with collaborators or others may require the company to relinquish rights to certain technologies or programs.
• The company's ability to generate product revenue or achieve profitability depends on the successful development and eventual commercialization of product candidates, which is uncertain.
• Expenses and capital requirements are expected to increase substantially as programs advance into clinical development and new research activities are initiated.
• The company is subject to risks similar to other clinical-stage biopharmaceutical companies, including dependence on key individuals, competition, and the need for regulatory approval.
• Geopolitical instability, armed conflict, inflation, interest rates, and stock market volatility could impact operations and ability to raise capital.
• Reliance on contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), including those located outside the United States (e.g., China), poses supply chain and operational risks.
• The company may not be able to establish, maintain, and enforce intellectual property rights covering its product candidates and platform.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for at least the next several years as it advances FHD-909 and other product candidates partnered with Lilly, continues preclinical and clinical development, identifies new research programs, and expands its platform capabilities. It anticipates increased costs related to operating as a public company and establishing commercialization infrastructure if products receive marketing approval. The company expects its current cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditure requirements for at least 12 months, but will require substantial additional funding thereafter.

Management Comments

• "We expect to continue to incur significant expenses and increasing operating losses for at least the next several years."
• "Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more product candidates we are developing or may develop."
• "We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: advance FHD-909 and other product candidates partnered with Lilly, and continue preclinical and clinical development of product candidates from our current portfolio; identify and advance additional research programs and additional product candidates; initiate preclinical testing for any new product candidates we identify and develop; obtain, maintain, expand, enforce, defend and protect our trade secrets and intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio; hire additional research and development personnel; add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and operations; expand the capabilities of our platform; acquire or in-license product candidates, intellectual property and technologies; experience significant operating cost increases as a result of increased inflation or increased tariffs; operate as a public company; seek marketing approvals for any product candidates that successfully complete clinical trials; and ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval."
• "As of the issuance date of these interim unaudited condensed consolidated financial statements the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months."

Industry Context

Foghorn Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting the chromatin regulatory system for oncology and other diseases. The strategic decision to discontinue independent development of FHD-286 and focus resources on the Lilly-partnered FHD-909 program aligns with a common industry trend of prioritizing high-potential assets and leveraging partnerships to de-risk development and share costs. The company's Gene Traffic Control platform aims to address a novel area of precision medicine, potentially differentiating it from competitors focusing on more traditional targets. The ongoing need for significant capital is typical for clinical-stage biotech companies, especially those with multiple programs in development.

Comparison to Industry Standards

• The company's continued operating losses and accumulated deficit are typical for a clinical-stage biopharmaceutical company that has not yet commercialized any products.
• The collaboration with Eli Lilly and Company for FHD-909, including 50/50 cost sharing, is a strong validation of the company's Gene Traffic Control platform and a common strategy for smaller biotechs to advance costly clinical programs with a larger pharmaceutical partner.
• The discontinuation of independent development for FHD-286, while a setback for that specific program, reflects a disciplined approach to pipeline management, similar to how many biotech companies prune their portfolios to focus on assets with higher probability of success or clearer paths to market.
• The cash runway of at least 12 months is generally considered acceptable for a clinical-stage biotech, though the stated need for additional future funding is a standard characteristic of the industry's capital requirements.

Legal Proceedings

• The company is not currently a party to any material litigation or legal proceedings that are probable to have a material adverse effect on its business.

Related Party Transactions

• The company has a consulting agreement with a scientific founder, with payments of $0.1 million for the six months ended June 30, 2025.
• Eli Lilly and Company is a 5% or greater shareholder in the company as of June 30, 2025, due to a stock purchase agreement.
• The company had a payable of $2.2 million to Eli Lilly and Company as of June 30, 2025, related to the collaboration agreement.

Stakeholder Impact

• **Shareholders:** Reduced net loss and lower cash burn may be viewed positively, but continued losses and the need for future capital raises could dilute existing holdings. The advancement of the Lilly partnership program (FHD-909) offers potential long-term value.
• **Employees:** Strategic discontinuation of FHD-286 programs might impact some roles, but continued investment in other programs and the Lilly partnership suggests ongoing R&D activity. The new lease in Watertown indicates potential for future growth and expansion of facilities.
• **Customers (Future):** Progress in clinical trials, particularly with FHD-909, brings the company closer to potentially offering new precision medicines for cancer patients.
• **Suppliers/Creditors:** Reduced cash burn and a stated 12-month cash runway provide some stability, but the long-term need for additional funding indicates continued reliance on external financing.
• **Partners (Eli Lilly and Company):** The continued collaboration and advancement of FHD-909 demonstrate a strong working relationship and shared commitment to the partnered programs.

Next Steps

• Continue preclinical and clinical development of product candidates from the current portfolio.
• Advance FHD-909 and other product candidates partnered with Eli Lilly and Company, with expected increasing enrollment for FHD-909.
• Identify and advance additional research programs and product candidates.
• Initiate preclinical testing for any new product candidates identified and developed.
• Obtain, maintain, expand, enforce, defend, and protect trade secrets and intellectual property portfolio.
• Hire additional research and development personnel.
• Add operational, legal, compliance, financial, and management information systems and personnel.
• Expand the capabilities of the Gene Traffic Control platform.
• Acquire or in-license product candidates, intellectual property, and technologies.
• Seek marketing approvals for any product candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure to commercialize any approved products.
• Obtain additional funding through equity offerings, debt financings, or collaborations/licensing arrangements as needed.
• Gain access to the new Watertown lease space in the fourth quarter of 2025 to perform tenant improvements.

Key Dates

Recommendation

Foghorn Therapeutics shows improved financial metrics with a reduced net loss and lower cash burn, which are positive signs for operational efficiency. The strategic focus on the Eli Lilly and Company partnered program, FHD-909, is a key value driver and de-risks development. However, the company remains clinical-stage with no product revenue, a substantial accumulated deficit, and an explicit need for significant future capital raises. While the current cash runway is stated as 12 months, the long-term funding requirement introduces uncertainty. Given the mixed signals of operational improvement and continued financial dependency, a 'hold' recommendation is appropriate for seasoned investors, awaiting further clinical data from FHD-909 and clarity on future financing strategies before considering a 'buy' or 'sell'.

Keywords

Biotechnology, Oncology, Clinical-stage, Gene Traffic Control, SMARCA2, FHD-909, Eli Lilly, Drug development, Biopharmaceutical, SEC filing, 10-Q, Financial results